Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96P26

UPID:
5NT1B_HUMAN

ALTERNATIVE NAMES:
Autoimmune infertility-related protein; Cytosolic 5'-nucleotidase IB

ALTERNATIVE UPACC:
Q96P26; B5MCR0; B7ZVX7; Q53RX2; Q8N9W3; Q8NA26; Q96DU5; Q96KE6; Q96M25; Q96SA3

BACKGROUND:
The enzyme Cytosolic 5'-nucleotidase 1B, known alternatively as Autoimmune infertility-related protein, is integral to the hydrolysis process of nucleotide monophosphates. This action results in the release of inorganic phosphate and nucleosides, notably AMP. Its function is critical in the regulation of nucleotide pools within cells, impacting various metabolic and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Cytosolic 5'-nucleotidase 1B offers a pathway to uncovering novel therapeutic approaches. Given its central role in nucleotide metabolism, targeting this enzyme could provide new avenues for treating metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.